Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
120 studies found for:    Melanoma (women OR woman OR female)
Show Display Options
Rank Status Study
21 Recruiting The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells
Condition: Cancer
Intervention:
22 Completed Microarray Analysis for Human Genetic Disease
Conditions: Breast Neoplasm;   Hereditary Neoplastic Syndrome;   Melanoma;   Ovarian Neoplasm
Intervention:
23 Active, not recruiting The Incidence of Breast and Other Cancers Among Female Flight Attendants
Conditions: Thyroid Cancer;   Breast Cancer;   Non-Melanoma Skin Cancer;   Melanoma
Intervention:
24 Terminated Assessment and Tracking of Long-term Alefacept Safety
Condition: Psoriasis
Intervention: Drug: Alefacept exposure
25 Completed
Has Results
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Conditions: Mucosal Lentiginous Melanoma;   Acral Melanoma;   Melanoma
Intervention: Drug: Nilotinib
26 Active, not recruiting STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Condition: Ocular Melanoma
Intervention: Drug: STA-9090
27 Completed Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
Conditions: Breast Cancer;   Genitourinary Cancer;   Malignant Female Reproductive System Neoplasm;   Melanoma;   Sarcoma
Intervention: Procedure: Punch Biopsy
28 Completed A Follow-up Study of Women Evaluated and Treated for Infertility
Conditions: Ovarian Cancer;   Breast Cancer;   Endometrial Cancer;   Thyroid Cancer;   Colrectal Cancer, Melanoma
Intervention:
29 Active, not recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
30 Recruiting Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
31 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
32 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
33 Completed An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Condition: Melanoma
Interventions: Drug: bortezomib;   Drug: sorafenib
34 Active, not recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Recurrent Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Dacarbazine;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
35 Recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
36 Recruiting Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma
Interventions: Drug: IMP321;   Drug: Pembrolizumab
37 Completed Sentinel Node and Endometrial Cancer
Condition: Endometrial Neoplasms
Intervention: Procedure: Detection of sentinel node
38 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
39 Unknown  The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients
Condition: Endometrial Cancer
Intervention:
40 Completed Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers
Conditions: Cervical Cancer;   Vulvar Cancer
Intervention: Device: SPECT/CT guided LM/SL

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.